Sarepta Therapeutics (NASDAQ:SRPT) Shares Down 5% – What’s Next?

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) traded down 5% during trading on Monday . The company traded as low as $126.19 and last traded at $126.69. 135,497 shares were traded during mid-day trading, a decline of 89% from the average session volume of 1,241,097 shares. The stock had previously closed at $133.34.

Wall Street Analysts Forecast Growth

Several research firms recently commented on SRPT. StockNews.com lowered shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, November 20th. Guggenheim increased their price objective on Sarepta Therapeutics from $148.00 to $150.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. William Blair raised Sarepta Therapeutics to a “strong-buy” rating in a research report on Friday, August 30th. Robert W. Baird decreased their price target on Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating for the company in a research report on Thursday, November 7th. Finally, Raymond James reissued an “outperform” rating and issued a $150.00 price target on shares of Sarepta Therapeutics in a research note on Thursday, October 10th. One analyst has rated the stock with a sell rating, two have issued a hold rating, twenty have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $175.77.

Sarepta Therapeutics Stock Performance

The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93. The stock has a market cap of $12.13 billion, a P/E ratio of 101.42 and a beta of 0.81. The firm’s 50-day moving average is $122.50 and its two-hundred day moving average is $131.48.

Hedge Funds Weigh In On Sarepta Therapeutics

Several hedge funds have recently bought and sold shares of SRPT. Janus Henderson Group PLC boosted its stake in shares of Sarepta Therapeutics by 14.2% during the 3rd quarter. Janus Henderson Group PLC now owns 4,358,511 shares of the biotechnology company’s stock worth $544,408,000 after acquiring an additional 543,143 shares in the last quarter. Wellington Management Group LLP raised its position in shares of Sarepta Therapeutics by 32.3% in the third quarter. Wellington Management Group LLP now owns 2,726,613 shares of the biotechnology company’s stock valued at $340,527,000 after purchasing an additional 665,087 shares during the period. Geode Capital Management LLC raised its position in shares of Sarepta Therapeutics by 2.7% in the third quarter. Geode Capital Management LLC now owns 1,696,354 shares of the biotechnology company’s stock valued at $211,910,000 after purchasing an additional 44,306 shares during the period. Jacobs Levy Equity Management Inc. lifted its stake in shares of Sarepta Therapeutics by 9.2% in the third quarter. Jacobs Levy Equity Management Inc. now owns 753,845 shares of the biotechnology company’s stock worth $94,148,000 after buying an additional 63,437 shares during the last quarter. Finally, Thrivent Financial for Lutherans boosted its holdings in shares of Sarepta Therapeutics by 6.3% during the 2nd quarter. Thrivent Financial for Lutherans now owns 644,675 shares of the biotechnology company’s stock worth $101,858,000 after buying an additional 37,940 shares during the period. 86.68% of the stock is owned by institutional investors and hedge funds.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.